+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Incidence of Bell's Palsy in 28 Major Markets 2019-2029

  • ID: 4900287
  • Report
  • October 2019
  • Region: Global
  • 80 pages
  • Black Swan Analysis
1 of 2
This Report Provides the Current incidence of Bell's Palsy in 28 Major Markets.
Bell’s palsy, also known as idiopathic facial nerve palsy, is a weakness of the muscles on one side of the face caused by the compression of the facial/cranial nerve, with no known underlying pathological cause. Such a condition typically manifests in a unilateral paralysis of the face. In rare cases, both sides of the face can be affected. Bell’s palsy is characterised by its rapid onset, reaching clinical peak within 72 hours. Most patients fully recover from Bell’s palsy.

This report provides the current incidence for Bell’s palsy across 28 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, China, Turkey, Mexico, Denmark, Egypt and South Korea, Argentina, Australia, Sweden, Denmark, Norway, Finland, The Netherlands, Poland, Russia, Switzerland, Austria ) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Bell’s palsy have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for the disease include:
  • Rapid onset of mild weakness to total paralysis on one side of the face
  • Facial droop
  • Drooling
  • Increased sensitivity to sound on the affected side
  • Headache
  • Synkinesis (involuntary facial movement)
  • Decrease in taste sensations
  • Pain around the jaw
  • Pain behind the ear on the affected side
  • Change in volume of tears/saliva that the individual may produce
This report is built using data and information sourced from our proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up-to date information from patient registries, clinical trials and epidemiology studies. All the sources used to generate the data and analysis have been identified and displayed in the report.

Reason to buy
  • Able to quantify patient populations in global Bell’s palsy market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the incidence of the subdivided types of Bell’s palsy and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Bell’s palsy incidence.
  • Identify sub-populations within Bell’s palsy which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Bell’s palsy patients.
Note: Product cover images may vary from those shown
2 of 2
  • Introduction
  • Cause Of The Disease
  • Risk Factors & Prevention
  • Diagnosis Of The Disease
  • Variation By Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Comorbid Conditions/Features Associated With The Disease
  • Methodology For Quantification Of Patient Numbers
  • Top-Line Prevalence/Incidence For Spinocerebellar Ataxia
  • Features Of Spinocerebellar Ataxia Patients
  • Spinocerebellar Ataxia Patients By Subtype
  • Spinocerebellar Ataxia Patients By Walking Capabilities
  • Spinocerebellar Ataxia Type 1 Patient Features
  • Spinocerebellar Ataxia Type 2 Patient Features
  • Spinocerebellar Ataxia Type 3 Patient Features
  • Spinocerebellar Ataxia Type 6 Patient Features
  • Spinocerebellar Ataxia Type 7 Patient Features
  • Undetermined Or Other Spinocerebellar Ataxia Patient Features
  • Abbreviations Used In The Report
  • Other Services & Solutions
  • Reports & Publications
  • Online Epidemiology Databases
  • Online Pharmaceutical Pricing Database
  • References
  • Appendix
List of Tables

Table 1. Prevalence of Spinocerebellar Ataxia, total (000s)
Table 2. Prevalence of Spinocerebellar Ataxia, males (000s)
Table 3. Prevalence of Spinocerebellar Ataxia, females (000s)
Table 4. Spinocerebellar Ataxia patients by subtype, total (000s)
Table 5. Spinocerebellar Ataxia patients by walking capability, total (000s)
Table 6. SCA1 patients with Babinski sign, total (000s)
Table 7. SCA1 patients with extrapyramidal signs, total (000s)
Table 8. SCA1 patients with hyperreflexia, total (000s)
Table 9. SCA1 patients with hyporeflexia, total (000s)
Table 10. SCA1 patients with nystagmus, total (000s)
Table 11. SCA1 patients with ophthalmoplegia, total (000s)
Table 12. SCA1 patients with pyramidal signs, total (000s)
Table 13. SCA1 patients with slow saccades, total (000s)
Table 14. SCA1 patients with spasticity, total (000s)
Table 15. SCA2 patients with Babinski sign, total (000s)
Table 16. SCA2 patients with dementia, total (000s)
Table 17. SCA2 patients with dysphagia, total (000s)
Table 18. SCA2 patients with extrapyramidal signs, total (000s)
Table 19. SCA2 patients with hyperreflexia, total (000s)
Table 20. SCA2 patients with hyporeflexia, total (000s)
Table 21. SCA2 patients with nystagmus, total (000s)
Table 22. SCA2 patients with ophthalmoplegia, total (000s)
Table 23. SCA2 patients with pyramidal signs, total (000s)
Table 24. SCA2 patients with slow saccades, total (000s)
Table 25. SCA2 patients with spasticity, total (000s)
Table 26. SCA3 patients with Babinski sign, total (000s)
Table 27. SCA3 patients with hyperreflexia, total (000s)
Table 28. SCA3 patients with hyporeflexia, total (000s)
Table 29. SCA3 patients with nystagmus, total (000s)
Table 30. SCA3 patients with ophthalmoplegia, total (000s)
Table 31. SCA3 patients with slowed saccades, total (000s)
Table 32. SCA3 patients with spasticity, total (000s)
Table 33. SCA6 patients with ophthalmoplegia, total (000s)
Table 34. SCA6 patients with pyramidal signs, total (000s)
Table 35. SCA7 patients with nystagmus, total (000s)
Table 36. SCA7 patients with ophthalmoplegia, total (000s)
Table 37. SCA7 patients with slowed saccades, total (000s)
Table 38. Undetermined or other SCA patients with nystagmus, total (000s)
Table 39. Undetermined or other SCA patients with ophthalmoplegia, total (000s)
Table 40. Undetermined or other SCA patients with slowed saccades, total (000s)
Table 41. Abbreviations and acronyms used in the report
Table 42. USA prevalence of Spinocerebellar Ataxia by 5-yr age cohort, males (000s)
Table 43. USA prevalence of Spinocerebellar Ataxia by 5-yr age cohort, females (000s)
Table 44. France prevalence of Spinocerebellar Ataxia by 5-yr age cohort, males (000s)
Table 45. France prevalence of Spinocerebellar Ataxia by 5-yr age cohort, females (000s)
Table 46. Germany prevalence of Spinocerebellar Ataxia by 5-yr age cohort, males (000s)
Table 47. Germany prevalence of Spinocerebellar Ataxia by 5-yr age cohort, females (000s)
Table 48. Italy prevalence of Spinocerebellar Ataxia by 5-yr age cohort, males (000s)
Table 49. Italy prevalence of Spinocerebellar Ataxia by 5-yr age cohort, females (000s)
Table 50. Spain prevalence of Spinocerebellar Ataxia by 5-yr age cohort, males (000s)
Table 51. Spain prevalence of Spinocerebellar Ataxia by 5-yr age cohort, females (000s)
Table 52. UK prevalence of Spinocerebellar Ataxia by 5-yr age cohort, males (000s)
Table 53. UK prevalence of Spinocerebellar Ataxia by 5-yr age cohort, females (000s)
Table 54. Japan prevalence of Spinocerebellar Ataxia by 5-yr age cohort, males (000s)
Table 55. Japan prevalence of Spinocerebellar Ataxia by 5-yr age cohort, females (000s)
Table 56. Netherlands prevalence of Spinocerebellar Ataxia by 5-yr age cohort, males (000s)
Table 57. Netherlands prevalence of Spinocerebellar Ataxia by 5-yr age cohort, females (000s)
Table 58. Norway prevalence of Spinocerebellar Ataxia by 5-yr age cohort, males (000s)
Table 59. Norway prevalence of Spinocerebellar Ataxia by 5-yr age cohort, females (000s)
Table 60. China prevalence of Spinocerebellar Ataxia by 5-yr age cohort, males (000s)
Table 61. China prevalence of Spinocerebellar Ataxia by 5-yr age cohort, females (000s)
Table 62. South Korea prevalence of Spinocerebellar Ataxia by 5-yr age cohort, males (000s)
Table 63. South Korea prevalence of Spinocerebellar Ataxia by 5-yr age cohort, females (000s)
Table 64. India prevalence of Spinocerebellar Ataxia by 5-yr age cohort, males (000s)
Table 65. India prevalence of Spinocerebellar Ataxia by 5-yr age cohort, females (000s)
Table 66. Australia prevalence of Spinocerebellar Ataxia by 5-yr age cohort, males (000s)
Table 67. Australia prevalence of Spinocerebellar Ataxia by 5-yr age cohort, females (000s)
Table 68. Portugal prevalence of Spinocerebellar Ataxia by 5-yr age cohort, males (000s)
Table 69. Portugal prevalence of Spinocerebellar Ataxia by 5-yr age cohort, females (000s)
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll